Newsroom
News and Media
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
September 14, 2021
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 07, 2021
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020
September 14, 2021
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 07, 2021
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020
Media Contact
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com
